Exploring the PHF6-RRM2 axis as a novel entry point for targeted therapy in neuroblastoma using in vitro and in vivo modeling
(2023)
- Author
- Lisa Depestel (UGent)
- Promoter
- Franki Speleman (UGent) and Kaat Durinck (UGent)
- Organization
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01HABTYEJK3PJANGCN9N380WC4
- MLA
- Depestel, Lisa. Exploring the PHF6-RRM2 Axis as a Novel Entry Point for Targeted Therapy in Neuroblastoma Using in Vitro and in Vivo Modeling. Ghent University. Faculty of Medicine and Health Sciences, 2023.
- APA
- Depestel, L. (2023). Exploring the PHF6-RRM2 axis as a novel entry point for targeted therapy in neuroblastoma using in vitro and in vivo modeling. Ghent University. Faculty of Medicine and Health Sciences, Ghent, Belgium.
- Chicago author-date
- Depestel, Lisa. 2023. “Exploring the PHF6-RRM2 Axis as a Novel Entry Point for Targeted Therapy in Neuroblastoma Using in Vitro and in Vivo Modeling.” Ghent, Belgium: Ghent University. Faculty of Medicine and Health Sciences.
- Chicago author-date (all authors)
- Depestel, Lisa. 2023. “Exploring the PHF6-RRM2 Axis as a Novel Entry Point for Targeted Therapy in Neuroblastoma Using in Vitro and in Vivo Modeling.” Ghent, Belgium: Ghent University. Faculty of Medicine and Health Sciences.
- Vancouver
- 1.Depestel L. Exploring the PHF6-RRM2 axis as a novel entry point for targeted therapy in neuroblastoma using in vitro and in vivo modeling. [Ghent, Belgium]: Ghent University. Faculty of Medicine and Health Sciences; 2023.
- IEEE
- [1]L. Depestel, “Exploring the PHF6-RRM2 axis as a novel entry point for targeted therapy in neuroblastoma using in vitro and in vivo modeling,” Ghent University. Faculty of Medicine and Health Sciences, Ghent, Belgium, 2023.
@phdthesis{01HABTYEJK3PJANGCN9N380WC4,
author = {{Depestel, Lisa}},
language = {{eng}},
pages = {{XII, 238}},
publisher = {{Ghent University. Faculty of Medicine and Health Sciences}},
school = {{Ghent University}},
title = {{Exploring the PHF6-RRM2 axis as a novel entry point for targeted therapy in neuroblastoma using in vitro and in vivo modeling}},
year = {{2023}},
}